There is no certainty that the buyout will come to pass, according to The Financial Times, which first reported the rumors.

We recently published 10 Stocks With Easy 15-30% Upside. Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the best-performing ...

Cancer vaccine experts are worried that if the Trump administration takes a hostile posture towards mRNA broadly, cancer ...

Swiss pharmaceutical giant Novartis is exploring a potential acquisition of U.S. biotech firm Avidity Biosciences, according ...

If a deal is confirmed and consummated, Novartis would claim ownership of a biotech that has raised something of a stir in ...

--Novartis made a takeover approach for Avidity Biosciences, a biotechnology company that specializes in rare diseases with a market value of $5.8 billion, the Financial Times reports, citing unnamed ...

Glencore maintains its UK listing; Britain seeks clarity on China's embassy plans; Novartis considers acquiring biotech firm ...